Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The objective of the study was to compare the efficacy of Magnevist (SH L 451 A) at doses of
0.1 mmol/kg and 0.2 mmol/kg in contrast-enhanced 3D-Magnetic Resonance Angiography in three
regions (abdominal, femoral, and leg regions) for visualization of arteries, evaluating 179
not assessable: caused by contrast media in the evaluation of structural abnormalities.
Magnevist (SH L 451 A) was administered intravenously in a crossover design in patients with
arterial disease in the abdominal to leg regions. The safety of the 0.2 mmol/kg dose was also
assessed.